CMB International Securities | Equity Research | Company Update



招商银行全资附属机构 A Wholly Owned Subsidiary Of China Merchants Banl

NWS Holdings (659 HK)

Waiting for multiple catalysts

NWS's annual results for the year ended 30 Jun 2021 (AOP +49% / net profit +353% YoY) were in line with the positive profit alert announced on 20 Jul. Core businesses' AOP +34% YoY, thanks to strong recovery in Roads and full-year contribution by Insurance. We lowered FY22E AOP/NAV by 6%/5%, and revised TP to HK\$11.48 having applied a larger discount to NAV. Valuations remain attractive, with 8.1% dividend yield. Maintain BUY. We identify some potential catalysts which might drive a re-rating.

- Recovery across business segments. All businesses, except Construction, recorded YoY improvements in Attributable Operating Profit (AOP). Excluding discontinued businesses (Environment & Transport), net profit to shareholders +121% YoY.
- Final DPS +3% under progressive dividend policy. Since FY19, NWS adopted a progressive dividend policy, keeping DPS steady in FY20 despite a slump in EPS. FY21 final DPS +3% to HK\$0.30, bringing full-year DPS to HK\$0.59 (HK\$0.58 in FY20).
- Maintain BUY, TP revised down to HK\$11.48. We revised FY22E/FY23E AOP by -6%/-1%, EPS by -25%/-16%, and FY22E NAV by -5%, mainly accounting for the prolonged impact from COVID. We lowered our target price to HK\$11.48, based on a 45% discount on FY22E NAV (previously 35% discount on FY21E NAV), to factor in the overall derating of HK/China market. Valuations remain attractive, with trailing P/B at 0.59x, 2 s.d. below 10-year average, and dividend yield at 8.1%, 2 s.d. above 10-year average. NWS's progressive DPS policy makes it a stable yield play with high dividend visibility.
- Potential catalysts to drive re-rating. While valuations are very attractive, we acknowledge that some catalysts are needed to drive valuations upward. These might include: 1) Acquisitions at attractive valuation to drive earnings growth, potentially in toll roads & modern logistics businesses; 2) HK-Mainland China border reopening to boost FTLife and Facilities Management; 3) resumption of global travel after vaccine rollout would benefit Aviation; 4) China's protective policies (still in discussion) to compensate for Roads' toll-exemption in Feb-May 2020; 5) further disposals of non-core assets.

Earnings Summary

(YE 30 Jun)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue (HK\$ mn)	22,612	28,197	32,380	36,180	38,853
Attributable operating profit (HK\$ mn)	3,514	5,226	5,081	5,656	6,208
YoY growth (%)	(25.3)	48.7	(2.8)	11.3	9.8
Profit to shareholders from continuing operations (HK\$ mn)	537	1,190	3,692	4,209	4,654
EPS (HK\$)	0.14	0.30	0.94	1.08	1.19
YoY growth (%)	(86.8)	121	210	14.0	10.6
Consensus EPS (HK\$)	N/A	N/A	0.95	1.15	N/A
P/E (x)	53.0	23.9	7.7	6.8	6.1
P/B (x)	0.61	0.59	0.54	0.50	0.46
Yield (%)	8.0	8.1	8.4	8.7	8.9
ROE (%)	1.1	2.5	7.4	7.7	7.8
Net gearing (%)	30.9	24.9	12.1	9.2	(2.5)

Source: Company data, Bloomberg, CMBIS estimates

BUY (Maintain)

Target Price HK\$11.48 (Previous TP HK\$13.70) Up/Downside +57.9% Current Price HK\$7.27

Conglomerate Sector

Daniel So, CFA (852) 3900 0857 danielso@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	28,434
Avg 3 mths t/o (HK\$ mn)	13.75
52w High/Low (HK\$)	9.55 / 6.03
Total Issued Shares (mn)	3,911.1
Source: Bloomberg	

Shareholding Structure

New World Development	60.86%
Courses LIVEy	

Share Performance

	Absolute	Relative
1-mth	-1.4%	6.3%
3-mth	-10.9%	4.9%
6-mth	-12.2%	5.7%

Source: Bloomberg

12-mth Price Performance



Source: Bloomberg

Auditor: PricewaterhouseCoopers

Related Reports:

- NWS Holdings (659 HK) Recovery on track post COVID-19 – 1 Mar 2021
- NWS Holdings (659 HK) –
 More disposals, more focus on Core business 13 Jan 2021
- 3. NWS Holdings (659 HK) Too cheap to ignore 5 Oct 2020
- NWS Holdings (659 HK) Selling loss-making bus business is a relief – 24 Aug 2020
- 5. NWS Holdings (659 HK) Profit warning no surprise 22 Jun 2020



FY21 Results Review

Figure 1: FY21 results review

Year ended 30 Jun HK\$ mn	FY20	FY21	YoY %	CMBIS FY21E	Diff. % Beat / (Miss)	Remarks
Revenue	25,921	28,197	9	15,521	(8)	
Attributable Operating Profit (AOP)	3,514	5,226	49	5,610	(7)	Recovery in Roads & full-period contribution of FTLife
Profit attributable to shareholders	253	1,147	353	1,185	(3)	Strong recovery from exceptionally low base, but partly offset by non-operating
EPS (HK\$)	0.06	0.29	383	0.30	(3)	provisions and remeasurement losses
DPS (HK\$)	0.58	0.59	2	0.59	-	Maintained progressive dividend policy, raising DPS for the first time since FY18

Source: Company data, CMBIS estimates

Figure 2: Attributable Operating Profit (AOP) by segment

				<u>, , , , , , , , , , , , , , , , , , , </u>			
Year ended HK\$ mn	30 Jun	FY20	FY21	YoY % Fav / (Unfav)	CMBI FY21E	Diff. % Beat / (Miss)	Remarks
	Roads	907	1,808	99	2,137	(15)	Rapid recovery, but interrupted by mini- outbreaks of COVID in some provinces
Core	Aviation	422	496	18	546	(9)	Collection rate and rental deferrals improved, as lessees benefited from vaccination rollouts, travel bubbles and gradual resumption of domestic flights
Business	Construction	1,066	949	(11)	862	10	Drop in AOP mainly due to associated co. Wai Kee's reclassification to AFS assets
	Insurance	750	972	29	948	3	Full-year contribution from FTLife, vs. 8- month contribution in FY20
	Sub-total	3,146	4,224	34	4,493	(6)	
	Continuing Operation	ons					
Core Business Strategic Portfolio	Logistics	628	663	6	692	(4)	Steady contribution by ATL Logistics Centre
	Facilities Mgmt.	(772)	(649)	16	(633)	(3)	Gleneagles Hospital HK achieved EBITDA breakeven since May 2021
	Strategic Invest.	277	739	167	802	(8)	Upward revaluation as market recovered
	Discontinued Opera	tions					
Business I Strategic Portfolio	Environment	355	244	(31)	252	(3)	Discontinued after announcing the disposals of SUEZ NWS and Derun in Jan 2021
	Transport	(119)	5	104	5	2	Discontinued after selling bus business in Oct 2020
	Sub-total	369	1,002	172	1,117	10	
Total AOP		3,514	5,226	49	5,610	(7)	

Source: Company data, CMBIS estimates

Figure 3: Earnings revision


	Ne	W	OI	d	Chang	e (%)	vs. Consensus (%)	
HK\$ mn	FY22E	FY23E	FY22E	FY23E	FY22E	FY23E	FY22E	FY23E
Revenue	32,380	36,180	35,466	36,065	(9)	0	4	7
Attributable Operating Profit (AOP)	5,081	5,656	5,430	5,710	(6)	(1)	N/A	N/A
-Core Business AOP	4,708	5,020	4,893	5,048	(4)	(1)	N/A	N/A
-Strategic Portfolio AOP	374	636	537	662	(30)	(4)	N/A	N/A
Profit attributable to shareholders	3,692	4,209	4,945	5,009	(25)	(16)	6	3
EPS (HK\$)	0.94	1.08	1.26	1.28	(25)	(16)	(1)	(6)

Source: Company data, Bloomberg, CMBIS estimates




Focus Charts

Figure 4: Progressive DPS despite fluctuating EPS




Source: Company data, CMBIS

Figure 6: Net gearing remains healthy




Source: Company data, CMBIS

Figure 8: Price-to-Book 2 s.d. below 10-yr average




Source: Company data, Bloomberg, CMBIS

Figure 5: Attributable Operating Profit by segment




Source: Company data, CMBIS

Figure 7: Capital recycling & streamlining business



Source: Company data, CMBIS

Figure 9: Dividend Yield 2 s.d. above 10-yr average



Source: Company data, Bloomberg, CMBIS



Financial Summary

Income statement						Cash flow summary					
YE 30 Jun (HK\$ mn)	FY20A	FY21A	FY22E	FY23E	FY24E	YE 30 Jun (HK\$ mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue	22,612	28,197	32,380	36,180	38,853	Net cash from operations	4,356	2,288	3,055	3,499	4,001
Roads	2,071	3,033	3,475	3,612	3,755	Finance costs paid	(857)	(857)	(857)	(857)	(857)
Construction	12,454	15,114	16,817	16,817	16,817	Interest received	1,436	1,436	1,436	1,436	1,436
Insurance	6,180	9,642	11,088	12,751	14,281	Hong Kong profits tax paid	(333)	(230)	(216)	(256)	(282)
Facilities Management	1,907	409	1,000	3,000	4,000	PRC & overseas tax paid	(498)	(461)	(433)	(511)	(565)
Transport (Discontinued)	3,308	-	-	-	-	Other operating activities	(4,333)	(6,516)	(1,000)	(1,000)	(1,000)
Cost of sales	(19,762)	(24,406)	(28,170)	(31,477)	(33,802)	Net cash from operating act	(229)	(4,339)	1,985	2,311	2,732
Gross profit	2,850	3,791	4,209	4,703	5,051	Dividends from associates	346	266	261	308	359
Other income/gains	1,002	2,027	2,088	2,150	2,215	Dividends from JV	1,657	1,281	2,067	2,184	2,335
General & admin expenses	(2,146)	(4,050)	(2,863)	(2,949)	(3,037)	Capital expenditures	(5,962)	3,500	(498)	(392)	5,595
Operating profit	1,707	1,768	3,434	3,905	4,228	Other investing activities	(9,429)	5,336	6,082	63	63
Finance costs	(967)	(839)	(839)	(839)	(839)	Net cash from investing	(13,389	10,383	7,912	2,163	8,352
Associated companies	(133)	266	261	308	359	Change in borrowings	11,887	(5,608)	(2,000)	(2,000)	(2,000)
JV	1,093	1,281	2,067	2,184	2,335	Dividends paid	(2,268)	(2,268)	(2,347)	(2,425)	(2,503)
Profit before income tax	1,700	2,476	4,924	5,558	6,084	Other financing activities	2,441	(730)	(618)	(618)	(618)
Income tax expenses	(590)	(691)	(649)	(767)	(847)	Net cash from financing	12,059	(8,606)	(4,965)	(5,043)	(5,121)
Profit from cont. operations	1,111	1,785	4,275	4,792	5,237	Net change in cash	(1,558)	(2,563)	4,932	(569)	5,963
Perpetual capital securities	(582)	(583)	(583)	(583)	(583)	Cash at the beginning of year	15,045	13,368	10,805	15,737	15,168
Non-controlling interests	8	(11)	-	-	-	Currency translation diff.	(120)	-	-	-	-
Net profit to shareholders	537	1,190	3,692	4,209	4,654	Cash at the end of year	13,368	10,805	15,737	15,168	21,131

Balance sheet						Key ratios					
YE 30 Jun (HK\$ mn)	FY20A	FY21A	FY22E	FY23E	FY24E	YE 30 Jun	FY20A	FY21A	FY22E	FY23E	FY24E
Non-current assets	110,226	106,132	109,424	112,795	116,380	AOP mix (%)					
Property, plant & equip.	4,882	1,186	1,186	1,186	1,186	Roads	25.8	34.6	42.5	40.2	38.6
Intangible concession right	14,084	14,356	13,600	13,359	13,117	Aviation	12.0	9.5	11.6	11.0	11.0
Associated companies	13,354	5,674	5,686	5,772	5,862	Construction	30.3	18.1	16.5	14.9	13.5
Joint ventures	12,288	10,806	10,806	10,806	10,806	Insurance	21.4	18.6	22.0	22.7	23.2
Other non-current assets	65,620	74,111	78,146	81,672	85,410	Logistics	17.9	12.7	11.4	10.5	9.8
						Facilities Management	(22.0)	(12.4)	(9.1)	(4.1)	(0.9)
Current assets	39,714	40,116	46,746	47,977	55,849	Strategic Investments	7.9	14.1	5.1	4.9	4.7
Cash and bank balances	13,222	10,805	15,737	15,168	21,131	Environment (Discontinued)	10.1	4.7	0.0	0.0	0.0
Trade & other receivables	16,208	15,162	16,072	17,036	18,058	Transport (Discontinued)	(3.4)	0.1	0.0	0.0	0.0
Other current assets	10,284	14,149	14,937	15,773	16,659						
Assets held for sale	112	6,325	-	-	-	P&L ratios (%)					
						Operating margin	7.5	6.3	10.6	10.8	10.9
Current liabilities	46,889	49,355	51,463	53,697	56,066	Net margin	2.4	4.2	11.4	11.6	12.0
Borrowings	4,064	2,119	2,119	2,119	2,119						
Trade & other payables	12,475	11,333	11,333	11,333	11,333	Balance sheet ratios					
Other current liabilities	30,350	35,904	38,012	40,246	42,614	Current ratio (x)	0.85	0.81	0.91	0.89	1.00
						Quick ratio (x)	0.84	0.81	0.90	0.89	0.99
Non-current liabilities	45,706	44,764	41,707	39,637	43,920	Net debt / equity ratio (%)	30.9	24.9	12.1	9.2	-2.5
Borrowings	26,892	23,229	21,229	19,229	17,229						
Deferred tax liabilities	2,286	1,925	1,925	1,925	1,925	Returns (%)					
Other non-current liabilities	16,528	19,609	18,552	18,482	24,766	ROE	1.1	2.5	7.4	7.7	7.8
						ROA	0.5	0.8	2.4	2.7	2.8
Shareholders' funds	46,367	47,913	52,459	56,896	61,699						
Perpetual capital securities	10,529	10,529	10,529	10,529	10,529	Per share (HK\$)					
Non-controlling interests	562	12	13	14	15	EPS	0.14	0.30	0.94	1.08	1.19
Total equity	57,458	58,454	63,000	67,438	72,243	DPS	0.58	0.59	0.61	0.63	0.65
						BVPS	11.9	12.3	13.4	14.5	15.8

Source: Company data, CMBIS estimates



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIS Ratings

BUY
Stock with potential return of over 15% over next 12 months
SELL
Stock with potential return of +15% to -10% over next 12 months
SELL
Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIS

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to US rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any US recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a US-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.